A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

NCT03460977 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration Resistant Prostate Cancer (mCRPC)
Small Cell Lung Cancer (SCLC)
Follicular Lymphoma (FL)

Interventions

DRUG: Mervometostat (PF-06821497)
DRUG: Enzalutamide
DRUG: Itraconazole

Sponsor

Pfizer